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The deposition of atherogenic lipoproteins such as oxidized
low-density lipoprotein (oxLDL) within the mesangium is
involved in the overproduction of extracellular matrix
proteins, a key event in the progression of glomerular
diseases including glomerulosclerosis. To clarify the
mechanisms underlying the oxLDL-induced production of
extracellular matrix proteins, we examined the possible
involvement of group IVA phospholipase A2 (PLA2) using
human mesangial cells and group IVA PLA2-deficient mouse
mesangial cells. oxLDL accelerated the production of
fibronectin and collagen (type IV), components of
extracellular matrix proteins, with the preceding release of
arachidonic acid. Methyl arachidonyl fluorophosphonate
(MAFP), known as an inhibitor of group IVA PLA2, markedly
suppressed the oxLDL-induced production of fibronectin as
well as the release of arachidonic acid, whereas it did not
inhibit the production of collagen. The inhibitory effect of
MAFP on the production of fibronectin was reversed by
adding arachidonic acid and 12-hydroxyeicosatetraenoic
acid. Furthermore, we found that in group IVA PLA2-deficient
mouse mesangial cells, the production of fibronectin in
response to oxLDL was weak as compared with that in
wild-type cells. However, the production by oxLDL of
collagen was not suppressed in the group IVA PLA2-deficient
cells. These findings suggest that group IVA PLA2 is involved
in the production of fibronectin in oxLDL-stimulated
mesangial cells.
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The development and progression of glomerular diseases
including glomerulosclerosis and diabetic nephropathy are
associated, in part, with glomerular lipid deposition involved
in pathobiological processes, including the transmigration
into the mesangium and differentiation into macrophages of
monocytes, the proliferation of mesangial cells, and the
deposition of mesangial extracellular matrix proteins.1–4 The
deposition of lipids within the mesangium results from the
accumulation of atherogenic lipoproteins such as low-density
lipoprotein (LDL) with hyperlipidemia/dyslipidemia in
diabetes mellitus or metabolic syndrome. LDL is shown to
induce the production of extracellular matrix proteins, such
as fibronectin and collagen, in mesangial cells5,6 and cell
proliferation,7 which are major cellular responses implicated
in the progression of glomerular diseases.
In the glomeruli, LDL is oxidized by mesangial cells to
generate oxidized LDL (oxLDL),8 which has been shown to
accumulate in sclerotic segments and mesangial areas in
human and experimental glomerular diseases.9,10 In addition
to LDL, oxLDL also exhibits numerous biological activities
including the generation of eicosanoids in human and rat
mesangial cells,8,11,12 the expression of adhesion molecules in
mouse glomerular endothelial cells,13 the adhesion of
monocytes to human mesangial cells,14 and the production
of fibronectin in human,14 mouse,15 and rat16 mesangial cells.
Among these cellular responses, the overproduction of
mesangial extracellular matrix proteins is a critical event
associated with glomerulosclerosis. Our recent study with rat
mesangial cells showed that the oxLDL-promoted production
of fibronectin is dependent, in part, on the generation of
reactive oxygen species.16 However, the mechanisms respon-
sible for the production of fibronectin in oxLDL-stimulated
mesangial cells have not been completely elucidated.
The transcription of the fibronectin gene is reported to be
promoted by 12-hydroxyeicosatetraenoic acid (12-HETE), a
lipoxygenase metabolite of arachidonic acid, in porcine
vascular smooth muscle cells.17 The generation of eicosanoids
depends on the liberation of arachidonic acid, which is
generally catalyzed by the hydrolytic action of phospholipase
A2 (PLA2) from membrane glycerophospholipids. Among a
number of PLA2 isoforms identified to date, group IVA PLA2
is considered to mediate the stimulus-induced release of
arachidonic acid, because the isoform is the only PLA2 that
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preferentially hydrolyzes glycerophospholipids bearing an
arachidonoyl residue at the sn-2 position.18,19 Recently, we
and other investigators reported that oxLDL activates group
IVA PLA2 to release free arachidonic acid in mouse peritoneal
macrophages.20,21 Consequently, it is possible that group IVA
PLA2 may act as a key enzyme that catalyzes the release of free
arachidonic acid as an initial step in the production of
fibronectin in oxLDL-stimulated mesangial cells. Taking this
possibility into account, the present study was undertaken to
examine the possible involvement of group IVA PLA2 in the
oxLDL-induced production of fibronectin using human
mesangial cells and group IVA PLA2-deficient mouse
mesangial cells.
RESULTS
Inhibition by MAFP of the oxLDL-induced production of
fibronectin but not collagen
Stimulation of human mesangial cells with oxLDL (20 mg/ml)
time-dependently (1–6 h) induced an increase in fibronectin
in the extracellular medium, as shown in Figure 1a. Although
this stimulatory effect is consistent with a previous report on
human mesangial cells,14 the mechanisms underlying the
oxLDL-promoted production of fibronectin have not been
completely elucidated. To examine the possible involvement
of group IVA PLA2, the effect of methyl arachidonyl
fluorophosphonate (MAFP), an inhibitor of group IVA
PLA2, was tested. The result shown in Figure 1b revealed
that pretreatment with MAFP (5–20 mmol/l) markedly
suppressed the oxLDL-promoted production of fibronectin
in a dose-dependent manner. Furthermore, the inhibitory
effect of MAFP was reversed when the MAFP (20 mmol/l)-
pretreated cells were stimulated with a combination of
oxLDL (20 mg/ml) and exogenous arachidonic acid (1 and
3 nmol/l) (Figure 1c). However, bromoenol lactone (BEL)
(20 mmol/l), an inhibitor of group VIA PLA2, had no effect
on the production of fibronectin induced by oxLDL (Figure
1d). Recently, we reported that N-acetylcysteine (1–5 mmol/
l), an antioxidant, prevents the production of fibronectin in
oxLDL-stimulated rat mesangial cells.16 In contrast, pretreat-
ment of human mesangial cells with N-acetylcysteine
(5 mmol/l) did not affect the oxLDL-promoted production
of fibronectin (Figure 1d). These results suggest the
involvement of group IVA PLA2 in the production of
fibronectin in oxLDL-stimulated human mesangial cells. As
12-HETE, a lipoxygenase metabolite of arachidonic acid, has
been suggested to be involved in the production of
fibronectin in porcine vascular smooth muscle cells,17 we
also examined this possibility. The results shown in Figure 2a
indicate that 12-HETE (10 and 50 nmol/l) overcame the
inhibitory effect of MAFP (20 mmol/l) on the oxLDL (20 mg/
ml)-induced production of fibronectin. We confirmed
that 12-HETE itself promoted the production of fibro-
nectin (Figure 2b). Furthermore, eicosatetraynoic acid
(ETYA) (1 mmol/l), an inhibitor of lipoxygenase, suppressed
the oxLDL (20 mg/ml)-induced production of fibronectin
(Figure 2c).
Figure 3a shows that oxLDL (20 mg/ml) also stimulated the
production of collagen (type IV) time-dependently (24 and
48 h). However, no significant increase was observed until
12 h after the stimulation (data not shown). MAFP
(5–20 mmol/l) did not inhibit the oxLDL-induced production
of collagen (Figure 3b), in contrast to the production of
fibronectin, indicating that the production of collagen is
independent of group IVA PLA2.
To examine whether oxLDL activates the hydrolytic action
of group IVA PLA2, the release of arachidonic acid was
evaluated using [3H]arachidonic acid-labeled mesangial cells.
As shown in Figure 4, stimulation with oxLDL (20 mg/ml)
time-dependently (1 and 3 h) induced an increase in free
[3H]arachidonic acid. The oxLDL-induced release of arachi-
donic acid was markedly suppressed by pretreatment with
MAFP (20 mmol/l).
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Figure 1 | Promotion by oxLDL of the production of fibronectin,
and inhibitory effects of MAFP on the production. (a) Human
mesangial cells were stimulated with or without oxLDL (20 mg/ml) for
the periods indicated. (b) Cells were treated with or without MAFP
(5–20 mmol/l) for 1 h, washed, and then stimulated with or without
oxLDL (20mg/ml) for 6 h. (c) Cells were treated with or without MAFP
(20mmol/l) for 1 h, washed, and then stimulated with or without
oxLDL (20 mg/ml) alone or in combination with arachidonic acid (AA,
1 or 3 nmol/l) for 6 h. (d) Cells were treated with or without BEL
(20mmol/l) for 1 h or N-acetylcysteine (5 mmol/l) for 24 h, washed, and
then stimulated with or without oxLDL (20 mg/ml) for 6 h. Fibronectin
in the extracellular medium was analyzed by immunoblotting, and its
amount shown in (c) was estimated by measuring the density of the
fibronectin band (mean7s.e.m.).
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oxLDL-induced fibronectin production in group IVA
PLA2-deficient mesangial cells
To verify the contribution of group IVA PLA2 to the oxLDL-
induced production of fibronectin, the ability of oxLDL to
promote the cellular response was compared between wild-
type and group IVA PLA2-deficient mouse mesangial cells.
We confirmed that no expression of group IVA PLA2 protein
was observed in the deficient mesangial cells, as shown in
Figure 5a. Under the conditions, although oxLDL (20 mg/ml)
promoted the production of fibronectin in both wild-type
and group IVA PLA2-deficient mouse mesangial cells, the
degree of augmentation by oxLDL was significantly weak in
the deficient cells, as compared with wild-type cells (Figure
5b). The amount of fibronectin, which changed little in the
deficient cells, was further increased by a combination of
oxLDL and exogenous arachidonic acid (5 nmol/l) (Figure
5c). In contrast to the production of fibronectin, the increase
in collagen induced by oxLDL (20 mg/ml) in group IVA
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Figure 3 | Effects of MAFP on the production of collagen induced
by oxLDL. (a) Human mesangial cells were stimulated with or
without oxLDL (20mg/ml) for the periods indicated. (b) Cells were
treated with or without MAFP (5–20 mmol/l) for 1 h, washed, and then
stimulated with or without oxLDL (20 mg/ml) for 48 h. Collagen in the
extracellular medium was analyzed by immunoblotting.
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Figure 2 | Effects of 12-HETE and ETYA on the production of
fibronectin. (a) Human mesangial cells were treated with or without
MAFP (20 mmol/l) for 1 h, washed, and then stimulated with or
without oxLDL (20mg/ml) alone or in combination with 12-HETE
(10 or 50 nmol/l) for 6 h. (b) Cells were stimulated with or without
12-HETE (10 or 50 nmol/l) for 6 h. (c) Cells were treated with or
without ETYA (1 mmol/l) for 1 h, and then stimulated with or
without oxLDL (20mg/ml) for 6 h. Fibronectin in the extracellular
medium was analyzed by immunoblotting.
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Figure 4 | Inhibitory effects of MAFP on the release of arachidonic
acid induced by oxLDL. [3H]Arachidonic acid-labeled human
mesangial cells were treated with or without MAFP (20mmol/l) for 1 h,
washed, and then stimulated with or without oxLDL (20 mg/ml) for
the periods indicated. Each value represents the mean7s.e.m. of
three separate experiments. *Po0.05, **Po0.01 versus oxLDL alone.
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Figure 5 | oxLDL-induced production of fibronectin and collagen
in group IVA PLA2-deficient mesangial cells. Mesangial cells were
prepared from wild-type (þ /þ ) and group IVA PLA2-deficient (/)
mice. (a) Group IVA PLA2 protein in mouse mesangial cells was
analyzed by immunoblotting. (b) Cells were stimulated with or
without oxLDL (20mg/ml) for 12 h. (c) Cells were stimulated with or
without oxLDL (20mg/ml) alone or in combination with arachidonic
acid (AA, 5 nmol/l) for 12 h. (d) Cells were stimulated with or without
oxLDL (20 mg/ml) for 48 h. Fibronectin or collagen in the extracellular
medium was analyzed by immunoblotting, and its amount shown
in (b) was estimated by measuring the density of the fibronectin
band (mean7s.e.m., *Po0.05 versus oxLDL alone).
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PLA2-deficient mesangial cells was not suppressed as
compared with that in wild-type cells (Figure 5d).
DISCUSSION
Lipid abnormalities in individuals with metabolic syndrome
and diabetes mellitus are involved in lipid deposition within
the mesangium, where atherogenic lipoproteins, such as LDL
and oxLDL, are accumulated. Along with growth factors and
inflammatory cytokines, these atherogenic lipoproteins
stimulate mesangial cells to promote the production of
extracellular matrix proteins,5,6,14–16 the accumulation of
which is involved in the progression of glomerular diseases
including glomerulosclerosis and diabetic nephropathy. We
demonstrated here that oxLDL accelerated the production of
fibronectin, a major matrix component, in human mesangial
cells (Figure 1). In this study, we examined the mechanisms
underlying the oxLDL-promoted production of fibronectin
in mesangial cells.
Our recent study showed that N-acetylcysteine, an
antioxidant, partially prevented the oxLDL-stimulated pro-
duction of fibronectin as well as generation of reactive oxygen
species in rat mesangial cells,16 suggesting the involvement of
reactive oxygen species in the cellular response. In contrast, in
human mesangial cells, the oxLDL-promoted production of
fibronectin was insensitive to N-acetylcysteine (Figure 1).
However, we have no explanation for the difference in
sensitivity to N-acetylcysteine between human and rat
mesangial cells at present.
Recently, it was reported that transcription of the
fibronectin gene is promoted by 12-HETE, a lipoxygenase
metabolite of arachidonic acid, in porcine vascular smooth
muscle cells.17 In numerous types of cells including mesangial
cells, the stimulus-induced release of free arachidonic acid
from membrane phospholipids is catalyzed by the hydrolytic
action of group IVA PLA2, which is the only PLA2 isoform
that preferentially hydrolyzes glycerophospholipids bearing
an arachidonoyl residue at the sn-2 position.18,19 Further-
more, oxLDL was shown to increase group IVA PLA2 activity
in bovine retinal pericytes22 and rat mesangial cells,12 and to
stimulate the group IVA PLA2-mediated release of arachi-
donic acid in mouse peritoneal macrophages.20 It is, there-
fore, possible that group IVA PLA2 participates in the
production of fibronectin in response to oxLDL. This
possibility is also provided by the present result that the
oxLDL-induced production of fibronectin was suppressed by
MAFP, an inhibitor of group IVA and VIA PLA2s, but not by
BEL, an inhibitor of group VIA PLA2 (Figure 1). Under the
conditions, MAFP actually prevented the release of arachi-
donic acid upon stimulation with oxLDL (Figure 4).
Furthermore, addition of exogenous arachidonic acid to the
MAFP-treated cells overcame the inhibitory effect of MAFP
on the oxLDL-promoted production of fibronectin (Figure 1).
These findings suggest that oxLDL induces the production of
fibronectin through the group IVA PLA2-mediated release of
arachidonic acid in human mesangial cells. This notion is
strongly supported by the present study with group IVA
PLA2-deficient mesangial cells indicating that the ability of
oxLDL to promote the production of fibronectin was
attenuated in group IVA PLA2-deficient cells compared with
control cells, and further that the impaired production was
accelerated by addition of exogenous arachidonic acid
(Figure 5). We further observed here that 12-HETE also
overcame the inhibitory effect of MAFP, and that the oxLDL-
induced production of fibronectin was suppressed by ETYA,
an inhibitor of lipoxygenase (Figure 2). Taken together, the
present results suggest that the oxLDL-promoted production
of fibronectin depends on the arachidonic acid cascade
mediated by group IVA PLA2 and lipoxygenase. Although
MAFP suppressed the oxLDL-induced production of fibro-
nectin to the level of unstimulated human mesangial cells,
oxLDL could still induce the production of fibronectin in
group IVA PLA2-deficient cells compared with control cells.
This might raise the possibility that MAFP inhibits the
production of fibronectin through other effects in addition to
the inhibitory effect on group IVA PLA2. However, as
exogenous arachidonic acid reversed the inhibition of the
production of fibronectin by MAFP that suppressed the
release of arachidonic acid, it is likely that the inhibitory
effect of MAFP results, at least in part, from the suppression
of group IVA PLA2.
The present study showed that oxLDL induced the
production of collagen with a preceding increase in
fibronectin in human mesangial cells, and further that MAFP
did not suppress the production of collagen (Figure 3).
Consistent with this, the oxLDL-promoted production of
collagen in group IVA PLA2-deficient mesangial cells was not
inhibited as compared with that in wild-type cells (Figure 5).
These findings suggest that group IVA PLA2 is not involved in
the oxLDL-promoted production of collagen. It has been
shown that the expression of collagen in response to LDL,
high-dose glucose, or hydroperoxide is mediated by trans-
forming growth factor b and connective tissue growth factor,
which are potent prosclerotic cytokines.6,23–25 oxLDL was
shown to stimulate the expression of transforming growth
factor b in human mesangial cells.26 Consequently, it is
conceivable that oxLDL promotes the production of collagen
through transforming growth factor b-mediated signaling
pathways. Furthermore, our results showed that in the
MAFP-treated human mesangial cells and the group IVA
PLA2-deficient mesangial cells, the oxLDL-promoted produc-
tion of collagen seems to be slightly enhanced as compared
with that in control condition (Figures 3 and 5). This might
result from suppression of negative effects of group IVA PLA2
on the transforming growth factor b-mediated signaling
pathways, because prostaglandin E2 was shown to inhibit
transforming growth factor b gene expression in rat
mesangial cells.27
Metabolic syndrome with dyslipidemia is considered to be
a risk factor in the development of chronic kidney disease.28
A recent study demonstrated that obesity in mice on a high-
fat diet causes renal lipid accumulation and glomerulo-
sclerosis with increases in fibronectin and collagen.29
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Furthermore, the expression of group IVA PLA2 has been
shown to be increased in the glomeruli of animal models of
renal diseases including type II diabetes.30–32 These findings
led us to assume that group IVA PLA2 is involved in the
hyperlipidemia-mediated progression of glomerular injury
with the deposition of extracellular matrix proteins. More-
over, the present study showed that inhibition or lack of
group IVA PLA2 resulted in a suppression of oxLDL-induced
production of fibronectin in mesangial cells. It is, therefore,
possible that regulation of group IVA PLA2 is beneficial in
glomerulosclerosis. To further clarify this possibility, experi-
ments with group IVA PLA2-deficient mice on a high-fat diet
are underway in our laboratory.
In summary, based on the present results, we suggest that
oxLDL stimulates the production of fibronectin, at least in
part, through the group IVA PLA2-mediated release of
arachidonic acid in human mesangial cells.
MATERIALS AND METHODS
Materials
Human native LDL (BT-903) and the anti-fibronectin antibody were
purchased from Biomedical Technologies Inc. (Stoughton, MI,
USA). The anti-collagen (type IV) antibody was from Rockland
Immunochemicals Inc. (Gilbertsville, PA, USA), the anti-group IVA
PLA2 antibody was from Santa Cruz Biotechnology Inc. (Santa
Cruz, CA, USA), MAFP was from BIOMOL Research Laboratories
Inc. (Plymouth Meeting, PA, USA), and [3H]arachidonic acid
(62.5 Ci/mmol) was from PerkinElmer Life Sciences Inc. (Boston,
MA, USA). 12(S)-HETE, ETYA, and BEL were from Cayman
Chemical (Ann Arbor, MI, USA). All other reagents were obtained
from Sigma (St Louis, MO, USA) and Wako Pure Chemical
Industries (Osaka, Japan).
Cell culture
Human mesangial cells (Cambrex Bio Science Walkersville Inc.,
Walkersville, MD, USA) were cultured in MCDB131 medium
supplemented with 10% heat-inactivated fetal bovine serum, 100 U/
ml penicillin, and 100 mg/ml streptomycin in collagen (type I)-
coated culture dishes (Asahi Techno Glass, Corp, Japan). The cells,
between the 6 and 10th passages, were plated in 35-mm dishes at
1 105 cells in MCDB131 medium containing 0.01% bovine serum
albumin, and placed in fresh MCDB131 medium just before use.
Mouse mesangial cells were obtained from a culture of glomeruli
isolated from group IVA PLA2-deficient and wild-type mice
(C57BL/6) by a sequential sieving technique (132 and 60 mm mesh
stainless-steel sieves), and grown in Rosewell Park Memorial
Institute 1640 medium supplemented with 10% heat-inactivated
fetal bovine serum, 5 U/ml penicillin, and 5 mg/ml streptomycin in
collagen (type I)-coated culture dishes. The cells, between the 5 and
10th passages, were plated in 35-mm dishes at 2 105 cells in
Rosewell Park Memorial Institute 1640 medium containing 0.01%
bovine serum albumin, and placed in fresh Rosewell Park Memorial
Institute 1640 medium just before use.
Preparation of oxLDL
The oxidation of LDL was performed as described previously.33
Briefly, human native LDL (2.5 mg protein/ml) was oxidized with
10 mmol/l CuSO4 at 371C for 3 h, and dialyzed against phosphate-
buffered saline containing 200 mmol/l ethylenediaminetetraacetic
acid at 41C. The oxLDL contained 10–15 nmol thiobarbituric acid-
reactive substances (TBARS)/mg protein, whereas native LDL
(before oxidation) contained 0.6–1.2 nmol TBARS/mg protein. The
relative electrophoretic mobility of the oxLDL was about 1.4 as
compared with that of native LDL.
Immunoblot analysis for fibronectin and collagen
The production of fibronectin and collagen by mesangial cells was
determined as described previously.34 Human or mouse mesangial
cells were treated and stimulated with various reagents including
oxLDL, as described in the figure legends. When human mesangial
cells were pretreated with MAFP, BEL, or N-acetylcysteine, the cells
were washed before the stimulation. The extracellular medium was
removed and centrifuged. The supernatant obtained was solubilized
with a buffer (2% sodium dodecyl sulfate, 1 mmol/l ethylenedi-
aminetetraacetic acid, 2 mmol/l ethyleneglycol tetraacetate, 2%
b-mercaptoethanol, 10% glycerol, 0.01% bromophenol blue, and
100 mmol/l Tris-HCl, pH 6.8), and subjected to sodium dodecyl
sulfate-polyacrylamide gel electrophoresis on a 5% gel. The
separated proteins were transferred onto a nitrocellulose membrane.
Antibodies against fibronectin or collagen were applied. The bound
antibodies were visualized using a peroxidase-conjugated secondary
antibody and enhanced chemiluminescence Western blotting
detection reagents (GE Healthcare Bio-Science Corp., Piscataway,
NJ, USA). Representative results of three separate experiments are
shown. To estimate the amounts of fibronectin, the density of each
band on a film was analyzed using a film scanner and National
Institute of Health image analysis software. The results are expressed
in arbitrary units.
Arachidonic acid release
Human mesangial cells were incubated with [3H]arachidonic acid
(1mCi/ml) for 12 h in MCDB131 medium containing 0.01% bovine
serum albumin. After being washed, the labeled cells were placed in
fresh MCDB131 medium containing 0.01% bovine serum albumin.
The cells were treated with MAFP for 1 h and then washed. After
treatment with BW755C (100 mmol/l), a dual inhibitor of cyclooxy-
genase and lipoxygenase, the cells were stimulated with oxLDL
for 1 or 3 h. Lipids in the medium and cells were extracted and
separated by thin-layer chromatography on a silica gel G plate
with petroleum ether/diethyl ether/formic acid (40:40:1, v/v/v) as
the development system. The area corresponding to free fatty
acid or other lipids was scraped off, and the radioactivity was
measured by liquid scintillation counting. The total radioactivity
of the fractions recovered from the plate was usually in the
range of 4.8 105–5.3 105 d.p.m. The radioactivity of each
lipid was corrected by adjusting the total radioactivity to 5.0
105 d.p.m.
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